Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS

Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)

NCT04563871 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

NCT06530719 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

NCT03133234 ·Status: COMPLETED

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

NCT05377788 ·Status: UNKNOWN

Osimertinib Study in Indian Patients

NCT03853551 ·Status: COMPLETED ·Phase: PHASE4

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

NCT06383728 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

NCT05528458 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

NCT02841579 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

NCT02908750 ·Status: COMPLETED ·Phase: PHASE1

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

NCT04816838 ·Status: RECRUITING ·Phase: NA

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519 ·Status: RECRUITING ·Phase: PHASE2

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

NCT06306456 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Osimertinib for Advanced EGFR-positive NSCLC Patients

NCT05037331 ·Status: RECRUITING

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

NCT03219970 ·Status: COMPLETED

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NCT05773092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

NCT07295821 ·Status: RECRUITING ·Phase: PHASE2

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

NCT05801029 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NCT05686434 ·Status: RECRUITING ·Phase: PHASE2

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer

NCT03804580 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA

NCT02769286 ·Status: COMPLETED ·Phase: PHASE2